Screener
Celcuity CELC Accrued Clinical Trial Costs
Accrued Clinical Trial Costs at other companies
Other financials
Where this comes from
Reported directly by Celcuity in its filing.
Tagged under the XBRL concept CELC:AccruedClinicalTrialCosts.
The source filing: Celcuity’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 5:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001493152-26-023180
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $10,454 | $6,407 |
| Accrued clinical trial costs | 8,771 | 16,826 |
| Other accrued expenses | 13,973 | 20,865 |
| Operating lease liabilities, current | 13 | 54 |
| Total current liabilities | 33,211 | 44,152 |
| Convertible notes | 195,566 | 195,324 |
Item 1. Financial Statements (unaudited) ITEM
FAQ
- What is Celcuity's accrued clinical trial costs?
- Celcuity (CELC) reported accrued clinical trial costs of $8.77M in Q1 2026.
- What does accrued clinical trial costs mean?
- This represents the estimated financial obligations incurred for clinical research activities that have been performed but not yet invoiced or paid by the company. It reflects the near-term cash outflow requirements necessary to sustain ongoing drug development programs and clinical trials.
Ask your AI about Celcuity's accrued clinical trial costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude